Camptothecin

製品コードS1288 別名:NSC-100880

Camptothecin化学構造

分子量(MW):348.35

Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.

サイズ 価格(税別) 在庫  
JPY 10300 あり
JPY 20200 あり
JPY 30200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(40)

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.
ターゲット
Topo I [2]
(Cell-free assay)
0.68 μM
体外試験

Camptothecin, a plant alkaloid orignially isolated from Camptotheca acuminate in 1966. [1] Camptothecin is noted to halt cells during the S phase of mitosis. Camptothecin displays nanomolar potency in cytotoxicity against many human tumor cell lines, including HT29, LOX, SKOV3, and SKVLB, with IC50 values ranging from 37 nM to 48 nM. [2] In combination with TNF, Camptothecin induces apoptosis in primary mouse hepatocytes, with an IC50 value of 13 μM. Camptothecin also abrogated the TNF-induced NF-κB Activation, as well as the expression of TNF-receptor associated factor 2 (TRAF2), X-linked inhibitor of apoptosis protein (X-IAP), and FLICE-inhibitory protein (FLIP). [4] In HCT116 cells, Camptothecin (5 μM) induces proteasome-mediated degradation of mixed lineage leukemia 5 (MLL5) protein, which leads to phosphorylation of p53 at Ser392. [5] Due to the low solubility and adverse effects of Camptothecin, various Camptothecin analogues have been developed, and two of them, topotecan and irinotecan, has been approved by FDA and are used in cancer chemotherapy.

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKOV3 M3;nfYN6fG:2b4jpZ4l1gSCjc4PhfS=> NGS2fWZKSzVyPUWxJI5O NUDxOnA{QTByM{WyNC=>
SKVLB MkDSZ5l1d3SxeHnjbZR6KGG|c3H5 NHS1XolKSzVyPUWzJI5O MkPpPVAxOzV{MB?=
HT29 MXjjfZRwfG:6aXPpeJkh[XO|YYm= NEnRXWNKSzVyPUi3Mlghdk1? M3riVFkxODN3MkC=
KB MXHjfZRwfG:6aXPpeJkh[XO|YYm= MXfJR|UxRThibl2= M3XwdlkxODN3MkC=
A427 NVPBVFNFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mkn5glEh|ryP NX7vVpVrTE2VTx?= M3rDcmlEPTB;MkSgcm0> NVzZVXRQQTh5NkGxNS=>
PC-3 NV\qT4l{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M133Zp4yKM7:TR?= MVnEUXNQ NIDRS|BKSzVyPUW3JI5O NX\reFhyQTh5NkGxNS=>
K562adr NGrtdZZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2T0WZ4yKM7:TR?= MnzqSG1UVw>? NWP5cJhkUUN3ME21O{BvVQ>? M3L6dlk5PzZzMUG=
MCF7mdr MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHSzcZF,OSEQvF2= MYrEUXNQ Mn\ZTWM2OD1|LkGgcm0> MUm5PFc3OTFz
P388 NEDJUpJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYnIVoZPUUN3ME2zNkBvVQ>? MkjuNVA{PDZ7M{O=
P388CPT5 R MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYK0OoV4UUN3ME2yMlgh|ryP Ml3SNVA{PDZ7M{O=
KBwt MnT3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYnDT|E1UUN3ME20NEBvVQ>? MU[xNFQyOTR5Nh?=
KBMDR NXvVV4dtT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWHJR|UxRTdyIH7N NXPHNWwyOTB2MUG0O|Y>
KBV20C NV3aNnNwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUXFSmhTUUN3ME2zNEBvVQ>? MUOxNFQyOTR5Nh?=
KB7D MonDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVPJR|UxRTN3IH7N NUX6cZdNOTB2MUG0O|Y>
KBCamp NUfXcFlVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHThcJRKSzVyPUGuNFQh|ryP NXq2Um4yOTB2MUG0O|Y>
HT29 NWrDWo1z[3m2b4TvfIlkcXS7IHHzd4F6 NFm4UnFKSzVyPUiwJI5O NGTPNVUyODh2MUiwPC=>
A549 NXfZSnFT[3m2b4TvfIlkcXS7IHHzd4F6 NXT2SYVrUUN3ME22O{BvVQ>? MlrBNVA5PDF6MEi=
T24 NFX2UmpkgXSxdH;4bYNqfHliYYPzZZk> M4ewW2lEPTB;OEigcm0> MomwNVA5PDF6MEi=
HOP-62 NUHRXItKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1W5bGlEPTB;MUCgcm0> M2Pn[lEyODJyMkiz
HCT-116 NE\LWnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MULJR|UxRTNyIH7N NH\rZnYyOTB{MEK4Ny=>
SF-539 NE\nW3BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVnJR|UxRTFyIH7N Mm\KNVExOjB{OEO=
UACC-62 MkXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVHJR|UxRTFyIH7N MYKxNVAzODJ6Mx?=
OVCAR-3 MoTpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUDJR|UxRTJ{MDDuUS=> NV\i[3l2OTFyMkCyPFM>
SN12C MlrCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHW2PGZKSzVyPUKwJI5O MoXaNVExOjB{OEO=
DU-145 Ml\yS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVXRXZVIUUN3ME2xNEBvVQ>? NFrudXYyOTB{MEK4Ny=>
MDA-MB-435 MnHwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEjSSWRKSzVyPUSwJI5O NXXJNGN{OTFyMkCyPFM>
WiDr MUPjfZRwfG:6aXPpeJkh[XO|YYm= Mk\aSG1UVw>? MXnJR|UxRTF5IH7N MYSxNVM{PDV4OR?=
A549 MXHjfZRwfG:6aXPpeJkh[XO|YYm= MXHEUXNQ NEOyXJFKSzVyPUG0JI5O MkPINVE{OzR3Nkm=
MKN45 M4HKO4N6fG:2b4jpZ4l1gSCjc4PhfS=> NFnPbWJFVVOR MmLFTWM2OD1zNzDuUS=> NFHUfJIyOTN|NEW2PS=>
SK-OV-3 M4X5foN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn71SG1UVw>? MXjJR|UxRTJyIH7N NHvQSpUyOTN|NEW2PS=>
H128 MYrjfZRwfG:6aXPpeJkh[XO|YYm= M3T5OGROW09? M2TlXmlEPTB;MUigcm0> MVSxNVM{PDV4OR?=
SK-BR-3 NUT0c5gy[3m2b4TvfIlkcXS7IHHzd4F6 MU\EUXNQ MULJR|UxRTJyIH7N MUWxNVM{PDV4OR?=
LX-1 MVTjfZRwfG:6aXPpeJkh[XO|YYm= MYTEUXNQ MoDlTWM2OD1zMkCgcm0> MVOxNVg2QDd|Nx?=
HCT116 NF7vV2RkgXSxdH;4bYNqfHliYYPzZZk> NHGzOFBFVVOR NHjNelJKSzVyPUmgcm0> MXexNVg2QDd|Nx?=
A2780 MV\jfZRwfG:6aXPpeJkh[XO|YYm= NYqyVVlZTE2VTx?= MUXJR|UxRTRibl2= NGTtVZoyOTh3OEezOy=>
IMR-32 NGG2dWVkgXSxdH;4bYNqfHliYYPzZZk> NEXIdnJ,OTBizszN M2XZVmROW09? MVHJR|UxRTJwMkGgcm0> NXG1TWl3OTJ4MUe4PVQ>
P388 Ml\QZ5l1d3SxeHnjbZR6KGG|c3H5 NGLNW4VKSzVyPUGzJI5O MUixNlYzODB6MR?=
Lewis MXvjfZRwfG:6aXPpeJkh[XO|YYm= NHXzTo5KSzVyPUOzJI5O MoXJNVI3OjByOEG=
JLC NFPWVYJkgXSxdH;4bYNqfHliYYPzZZk> MmT4TWM2OD13Lk[gcm0> NYCxTZpTOTJ4MkCwPFE>
HT-29 NE\uO2xkgXSxdH;4bYNqfHliYYPzZZk> MnvsTWM2OD1zLkSg{txO MmW3NVI3Ozl3NEG=
Caki-2 M3XkWIN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml\TTWM2OD1|Lkm2JO69VQ>? Mn\lNVI3Ozl3NEG=
A549 MmjhZ5l1d3SxeHnjbZR6KGG|c3H5 M{P4cGlEPTB;Mj61N{DPxE1? MX6xNlY{QTV2MR?=
HEC-1-B NFu2U3JkgXSxdH;4bYNqfHliYYPzZZk> MVrJR|UxRThwNkSg{txO NYPQeGljOTJ4M{m1OFE>
HL-60 MWXjfZRwfG:6aXPpeJkh[XO|YYm= NIm4ZVlKSzVyPU[2JI5O NGO5Z2YyOjZ|OUW0NS=>
Col2 NV;4fZJr[3m2b4TvfIlkcXS7IHHzd4F6 NF;SRYZ,OSEQvF2= M2L6bGVFPTB;NUegcm0> NVTseYtzOTVyNEO0NFc>
HUVEC NIrlPG9kgXSxdH;4bYNqfHliYYPzZZk> MlvtglEh|ryP MnnZSWQ2OD1{NUigcm0> MmnkNVUxPDN2MEe=
KB M{noWIN6fG:2b4jpZ4l1gSCjc4PhfS=> MlzSglEh|ryP Mn;oSWQ2OD1{MjDuUS=> M4Xp[|E2ODR|NEC3
LCNaP NGKyV2lkgXSxdH;4bYNqfHliYYPzZZk> NH3GUWt,OSEQvF2= MVPFSFUxRTJ6IH7N M4DrO|E2ODR|NEC3
Lu1 NVzUSpc5[3m2b4TvfIlkcXS7IHHzd4F6 NV\ne4V7hjFizszN NXvIUmFCTUR3ME2yPUBvVQ>? NUHIUotoOTVyNEO0NFc>
RPMI8402 NXn5fpdi[3m2b4TvfIlkcXS7IHHzd4F6 MUj+NVAh|ryP MVfJR|UxRTZibl2= MnraNVU1QDJ7Mkm=
CPT-K5 MWHjfZRwfG:6aXPpeJkh[XO|YYm= MoT5glExKM7:TR?= NITjSZdKSzVyPkGwJO69VQ>? MlPSNVU1QDJ7Mkm=
P388 M{eyTYN6fG:2b4jpZ4l1gSCjc4PhfS=> NInhV3F,OTBizszN MYPJR|UxRTF2IH7N NUfoW|M2OTV2OEK5Nlk>
P388/CPT45 NH:yfZVkgXSxdH;4bYNqfHliYYPzZZk> MWr+NVAh|ryP NYPjcIlXUUN3ME6xNEDPxE1? MXyxOVQ5Ojl{OR?=
KB3-1 Mn\YZ5l1d3SxeHnjbZR6KGG|c3H5 MWL+NVAh|ryP NWe1eHJoUUN3ME20NEBvVQ>? M3zzeFE2PDh{OUK5
KBV-1 + MDR1 MkPWZ5l1d3SxeHnjbZR6KGG|c3H5 NGX6RpV,OTBizszN MYHJR|UxRTR2MDDuUS=> M2WwUFE2PDh{OUK5
KBH MYDjfZRwfG:6aXPpeJkh[XO|YYm= NWLWelB7hjFyIN88US=> NX\WVYxMUUN3ME20OFAhdk1? NGrsO28yPTR6MkmyPS=>
HOP-62 MX\jfZRwfG:6aXPpeJkh[XO|YYm= MWL+NVAh|ryP M1fDN2dKPTB;MUCgcm0> MnrYNVU2ODlzNkS=
HCT-116 MkfkZ5l1d3SxeHnjbZR6KGG|c3H5 NXrJfGVbhjFyIN88US=> MX3HTVUxRTNyIH7N M{HzR|E2PTB7MU[0
F-539 NIrzdWZkgXSxdH;4bYNqfHliYYPzZZk> NHPKTnh,OTBizszN MlzUS2k2OD1zMDDuUS=> MoX6NVU2ODlzNkS=
UACC-62 M3LOZYN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml;5glExKM7:TR?= Mkn3S2k2OD1zMDDuUS=> MW[xOVUxQTF4NB?=
OVCAR-3 M{TJfIN6fG:2b4jpZ4l1gSCjc4PhfS=> MoPIglExKM7:TR?= MWfHTVUxRTJ{MDDuUS=> MVexOVUxQTF4NB?=
SN12C M1nKU4N6fG:2b4jpZ4l1gSCjc4PhfS=> NEDTRYp,OTBizszN NXXBdVBtT0l3ME2yNEBvVQ>? M3\yRVE2PTB7MU[0
DU-145 MVfjfZRwfG:6aXPpeJkh[XO|YYm= NH3j[HB,OTBizszN M{\XeGdKPTB;MUCgcm0> M4DFXVE2PTB7MU[0
MDA-MB-435 NFzH[WtkgXSxdH;4bYNqfHliYYPzZZk> MXj+NVAh|ryP M2noVWdKPTB;NECgcm0> MmrQNVU2ODlzNkS=
MT-4 M3nSUYN6fG:2b4jpZ4l1gSCjc4PhfS=> MXvJR|UxRTRibl2= NU\aZlZDOTd{NUS2Olk>
CCRF-CEMc M3LNeIN6fG:2b4jpZ4l1gSCjc4PhfS=> M2\PdmlEPTB;MzDuUS=> MlvqNVczPTR4Nkm=
WIL-2NSd MWrjfZRwfG:6aXPpeJkh[XO|YYm= MVzJR|UxRTVibl2= MYmxO|I2PDZ4OR?=
CCRF-SB MYXjfZRwfG:6aXPpeJkh[XO|YYm= NGfqbFhKSzVyPUOgcm0> MmDjNVczPTR4Nkm=
CRL 7065 NUGxfWJ5[3m2b4TvfIlkcXS7IHHzd4F6 NIj2S2ZKSzVyPUSwNEBvVQ>? NVXIUZU6OTd{NUS2Olk>
SK-MEL-28b NFm1W|ZkgXSxdH;4bYNqfHliYYPzZZk> MnjFTWM2OD12MDDuUS=> NFjsNWEyPzJ3NE[2PS=>
MCF-7 MXnjfZRwfG:6aXPpeJkh[XO|YYm= MmP2TWM2OD12MDDuUS=> NFq3RY4yPzJ3NE[2PS=>
SKMES-1 MYnjfZRwfG:6aXPpeJkh[XO|YYm= NIK5R4RKSzVyPUGwJI5O MoHWNVczPTR4Nkm=
HepG2 M3LIWYN6fG:2b4jpZ4l1gSCjc4PhfS=> M3jBTWlEPTB;M{Cgcm0> NFX4NGcyPzJ3NE[2PS=>
DU145 NYDiXWhJ[3m2b4TvfIlkcXS7IHHzd4F6 M{LNbmlEPTB;MUCgcm0> MnSwNVczPTR4Nkm=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Cyclin1 / CDK1 / CDK2 ; 

PubMed: 29963130     


Western blot analysis indicated that camptothecin (6 µM) downregulates the expression of cell-cycle-associated proteins, cyclin 1, CDK1 and CDK2 in NPC cells. β-actin was used as a loading control.

Vimentin / Fibronectin / E-cadherin ; 

PubMed: 29963130     


Western blot analysis revealed that camptothecin (6 µM) treatment downregulates the expression of vimentin and fibronectin, and upregulates the expression of E-cadherin in NPC cells. β-actin was used as a loading control. NPC, nasopharyngeal carcinoma.

TGF-β / PI3K / pPI3K / AKT / pAKT ; 

PubMed: 29963130     


Western blot analysis revealed that camptothecin (6 µM) treatment inhibits the expression of TGF-β, PI3K and AKT in NPC cells. 

p53 / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 17548347     


NPCs in trophic factor-containing media were treated with 10 μM camptothecin for 0, 2, 4, 6, or 8 h, and extracts were immunoblotted for p53, active cleaved caspase-3, cleaved PARP, and total GSK3α/β as a loading control.

29963130 17548347
体内試験 Camptothecin (8 mg/kg) displays complete growth inhibition and regression in mice xenografts of various tumors, including colon, lung, breast, stomach, and ovary tumors. [3] In mice, combinations of Camptothecin (50 mg/kg) and TNF (5 and 7 μg/kg), but not Camptothecin alone, induces liver damage. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[2]
- 合併

Topoisomerase I Cleavable Complex Assay:

Topoisomerase I is isolated from calf thymus and is devoid of topoisomerase II. All reactions are carried out in 10 mL volumes of reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.5 mM EDTA, and 30 pg/mL BSA) in microtiter plates. Camptothecin is dissolved in DMSO at 10 mg/mL and serially diluted in 96-well microtiter plates to which the 32P end-labeled pBR322 DNA and topoisomerase enzyme are added. The reaction mixture is incubated at room temperature for 30 min and then the reaction stopped by adding 2 mL of a mixture of sodium dodecyl sulfate and proteinase K (1.6% and 0.14 mg/mL final concentrations, respectively). The plates are heated at 50 °C for 30 min, 10 mL of standard stop mixture containing 0.45 N NaOH is added in order to generate single-stranded DNA, and the samples are electrophoresed in 1.5% agarose gels in TBE buffer. Gels are blotted on nitrocellulose paper, dried, and exposed to X-ray film. The units of cleavage are calculated from the autoradiographs and plotted against the log drug concentration. The IC50 values are then obtaine
細胞試験: [2]
- 合併
  • 細胞株: U87MG, A549 and H838 cells
  • 濃度: 0.17 nM–10 mM
  • 反応時間: 48 hours
  • 実験の流れ: Tumor cells are plated in 100 μL of medium in 96-well microtiter plates at a density of 1500 to 4000 cells per well and allowed to adhere overnight. Cells are incubated with Camptothecin for 48 hours and then with fresh medium for 48 hours. Camptothecin at each concentration is added in quadruplicate. Following a 4-hour incubation of treated cells with MTT, the reduced dye product is extracted from the cells with 0.2 mL of DMSO followed by 50 μL of Sorensen's buffer. The plates are shaken briefly, and the absorbance at 570 nm is read and quantitated. Curves are fitted to the MTT assay data using a four-parameter logistic equation.
    (参考用のみ)
動物試験:[3]
- 合併
  • 動物モデル: Nude mice (NIH-I high fertility strain) bearing xenografts of CASE, SW48, DOY, SPA, and CLO cells
  • 製剤: Finely grounded and dispersed in intralipid 20% at 1 mg/mL by sonication
  • 投薬量: 0–8 mg/kg
  • 投与方法: Administered via i.m. or i.v. injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 3 mg/mL (8.61 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 348.35
化学式

C20H16N2O4

CAS No. 7689-03-4
保管
in solvent
別名 NSC-100880

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Camptothecinを買う | Camptothecin ic50 | Camptothecin供給者 | Camptothecinを購入する | Camptothecin費用 | Camptothecin生産者 | オーダーCamptothecin | Camptothecin化学構造 | Camptothecin分子量 | Camptothecin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID